AXIM
AXIM BIOTECHNOLOGIES, INC.Company Information
- Company Name
- AXIM BIOTECHNOLOGIES, INC.
- CIK
- CIK0001514946
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AXIM: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AXIM
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-01-30
- Last sale
- —
- Shares purchased (TTM)
- 1,086,216
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2022-12-31
- Institutional shares owned
- 500
- Shares outstanding
- 171,893,796
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2024-08-19
- Price on filing date
- —
- 1-month reaction
- -30.00%
- 3-month reaction
- -60.00%
Balance Sheet
Values in millions ($)| Line item | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Convertible Preferred Stock Series B | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
Current Assets | ||||||||||||||||||
| Convertible Preferred Stock Series C | - | - | - | - | 0 | 0 | 0 | 0 | -0 | 1 | 0 | 1 | ||||||
| Cash | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current And Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | - | - | 0 | 0 | - | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Inventory Net | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | ||||||
| Other Assets Current | - | - | - | - | - | 0 | 0 | - | - | - | 0 | - | ||||||
| Supplies | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | 4 | 4 | - | - | - | - | - | - | - | ||||||
| Other Intangible Assets Net | 3 | 3 | 4 | - | - | 4 | 4 | - | - | - | 4 | - | ||||||
| Security Deposit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 7 | ||||||
| Inventory Work In Process | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Assets Noncurrent | ||||||||||||||||||
| Notes Receivable Related Parties | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Other Assets | ||||||||||||||||||
| Other Assets | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 14 | ||||||
| Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 2 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 14 | ||||||
| Accounts Payable And Other Accrued Liabilities | - | - | - | - | - | 1 | 1 | - | - | - | 1 | - | ||||||
| Due To Officers Or Stockholders Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 2 | 2 | 3 | 1 | 1 | - | 1 | 1 | 1 | 1 | - | 1 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Derivative Liabilities | - | - | - | - | - | - | - | - | 2 | 2 | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Capital Lease Obligations | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | ||||||
| Liabilities Current | 7 | 5 | 6 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Capital Lease Obligations Current | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Other Liabilities Current | - | - | 0 | 0 | - | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Long Term Debt And Capital Lease Obligations Current | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Deferred Revenue Current | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - | ||||||
| Unsecured Debt Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Notes Payable Current | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Short Term Borrowings | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Derivative Liabilities Current | 4 | 2 | 2 | 2 | 7 | 1 | 2 | - | - | - | 0 | - | ||||||
| Deferred Tax Liabilities | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | 0 | 0 | - | 2 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Deferred Revenue | - | - | - | - | - | 0 | 0 | - | - | - | 0 | - | ||||||
| Convertible Debt Noncurrent | 5 | 5 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Convertible Debt Current | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 7 | 7 | 6 | 6 | 6 | 5 | 6 | 6 | 6 | 5 | 5 | 8 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | - | 4 | 4 | 4 | - | 4 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Convertible Notes Payable | - | - | 4 | 4 | 4 | 4 | 4 | - | - | - | 1 | - | ||||||
| Capital Lease Obligations Noncurrent | - | - | 0 | - | - | - | 0 | - | 0 | 0 | 0 | - | ||||||
| Long Term Debt And Capital Lease Obligations | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 13 | 11 | 12 | 10 | 14 | 10 | 9 | 9 | 8 | 8 | 8 | 10 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | 0 | - | 0 | - | - | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Share Subscribed But Unissued Subscriptions Receivable | - | - | -0 | - | - | -0 | -0 | - | - | 0 | 0 | 4 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -10 | -7 | -8 | -6 | -10 | -6 | -5 | -4 | -3 | -3 | -2 | 5 | ||||||
| Stockholders Equity Note Subscriptions Receivable | -0 | -0 | - | -0 | -0 | - | - | -0 | -0 | - | - | - | ||||||
| Common Stock Held By Subsidiary | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Additional Paid In Capital | 65 | 65 | 65 | 64 | 61 | 61 | 59 | 59 | 57 | 56 | 51 | 50 | ||||||
| Retained Earnings Accumulated Deficit | -75 | -72 | -72 | -70 | -71 | -67 | -64 | -63 | -61 | -60 | -58 | -50 | ||||||
| Liabilities And Stockholders Equity | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 14 | ||||||
| Series B Convertible Preferred Stock | - | - | - | -0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Convertible Note Payable | - | - | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Note Payable Related Party | 0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | ||||||
| Debt Instrument Unamortized Discount | - | - | - | 2 | 2 | - | - | - | - | - | 1 | 1 | ||||||
| Convertible Note Payable Noncurrent | - | - | 0 | - | - | 0 | 0 | - | - | - | 0 | - | ||||||
| Convertible Notes Payable Non Current Related Party | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Interest Payable Current | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Promissory Note Related Party | - | - | - | - | - | - | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 4 | - | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 300 | 300 | 1,000 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 294 | 278 | 246 | 238 | 228 | 224 | 192 | 185 | 163 | 152 | 138 | 136 | ||||||
| Shares Outstanding | 294 | 278 | 246 | 238 | 228 | 224 | 192 | 138 | 138 | 152 | 138 | 136 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAXIM BIOTECHNOLOGIES, INC. (AXIM) — SEC Financial Statements & Analysis
AXIM BIOTECHNOLOGIES, INC. (AXIM) is a pharmaceutical preparations company, incorporated in NV. AXIM BIOTECHNOLOGIES, INC. trades on OTC as: AXIM. AXIM BIOTECHNOLOGIES, INC. (AXIM)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-19. Based on that filing, AXIM BIOTECHNOLOGIES, INC. carries a market cap of $2.94M, a P/E ratio of -0.71x, a P/B ratio of -0.31x, a P/S ratio of 31.78x, an enterprise value of $3.13M, and an EV/EBITDA multiple of -1.66x. On profitability, it posts a gross margin of -18.88%, an operating margin of -2497.01%, a net margin of -4463.98%, a Return on Equity (ROE) of 42.89%, a Return on Assets (ROA) of -103.73%, and a Return on Invested Capital (ROIC) of -192.82%. Per share, it reports EPS of $-0.01, diluted EPS of $-0.01, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 253.61% year-over-year, net income growth of -56.09% year-over-year, and EPS growth of -66.26% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-6.55M, a debt-to-equity ratio of -1.39x, a debt ratio of 3.56, an interest coverage ratio of -5.69x, free cash flow of $-761.83K (TTM), and net debt of $180.45K. Figures sourced from SEC EDGAR.
- Market Cap
- $2.94M
- P/E TTM
- -0.71x
- EPS TTM
- $-0.01
- P/B TTM
- -0.31x
- ROE TTM
- 42.89%
- ROA TTM
- -103.73%
- Debt To Equity
- -1.39x
- Free Cash Flow TTM
- $-761.83K
- Net Revenue TTM Growth 1Y
- 253.61%
Data as of 2024-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AXIM BIOTECHNOLOGIES, INC. in?
AXIM BIOTECHNOLOGIES, INC. (AXIM) operates in the Pharmaceutical Preparations industry.
What exchange does AXIM trade on?
AXIM BIOTECHNOLOGIES, INC. (AXIM) trades on the OTC.
Where is AXIM BIOTECHNOLOGIES, INC. incorporated?
AXIM BIOTECHNOLOGIES, INC. is incorporated in NV.
When was AXIM BIOTECHNOLOGIES, INC. (AXIM)'s most recent SEC filing?
AXIM BIOTECHNOLOGIES, INC. (AXIM)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-19.
What is AXIM's market cap?
AXIM BIOTECHNOLOGIES, INC. (AXIM) has a market capitalization of $2.94M as of 2024-06-30.
What is AXIM's EPS (earnings per share)?
AXIM BIOTECHNOLOGIES, INC. (AXIM)'s trailing twelve month EPS is $-0.01 as of 2024-06-30.
What is AXIM's ROE (return on equity)?
AXIM BIOTECHNOLOGIES, INC. (AXIM)'s trailing twelve month Return on Equity (ROE) is 42.89% as of 2024-06-30.
What is AXIM's ROA (return on assets)?
AXIM BIOTECHNOLOGIES, INC. (AXIM)'s trailing twelve month Return on Assets (ROA) is -103.73% as of 2024-06-30.
What is AXIM's ROIC (return on invested capital)?
AXIM BIOTECHNOLOGIES, INC. (AXIM)'s trailing twelve month Return on Invested Capital (ROIC) is -192.82% as of 2022-09-30.
What is AXIM's EV/EBITDA?
AXIM BIOTECHNOLOGIES, INC. (AXIM)'s trailing twelve month EV/EBITDA is -1.66x as of 2024-06-30.